|
80 |
Draft Q&A Guidance Offers Roadmap For Biosimilar Post-approval Changes
|
sureAssist |
2024-12-26 |
202 |
|
79 |
10 points on how the FDA's CDER monitors the Quality of Medicinal Products
|
sureAssist |
2024-12-26 |
194 |
|
78 |
The difference between an ISO 17025 certified laboratory and an ISO 9001 one
|
sureAssist |
2024-12-26 |
196 |
|
77 |
This Week at FDA: Updated guidance on denying inspections and biosimilar interchangeability
|
sureAssist |
2024-12-26 |
192 |
|
76 |
Are Annex 1's CCS Requirements Still Challenging You?
|
sureAssist |
2024-12-26 |
186 |
|
75 |
Requalification of an Automatic Inspection System (AVI)
|
sureAssist |
2024-12-26 |
190 |
|
74 |
EMA: Update of the Annex to the Excipients Guideline
|
sureAssist |
2024-12-26 |
187 |
|
73 |
New FDA Draft Guidance: Data Integrity For In Vivo Bioavailability And Bioequivalence Studies
|
sureAssist |
2024-12-26 |
203 |
|
72 |
Euro Roundup: MHRA outlines potential impact of AI on medical products regulation
|
sureAssist |
2024-12-26 |
194 |
|
71 |
4 things the first-ever RCC credential holders want you to know
|
sureAssist |
2024-12-26 |
193 |
